Optimi Health Corp. (CSE:OPTI)

Canada flag Canada · Delayed Price · Currency is CAD
6.55
-0.20 (-2.96%)
Jun 10, 2026, 3:59 PM EST
Market Cap36.85M +124.3%
Revenue (ttm)231.86K -53.2%
Net Income-5.40M
EPS-1.68
Shares Out 5.63M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,818
Open6.71
Previous Close6.75
Day's Range6.55 - 7.00
52-Week Range3.15 - 12.60
Beta1.60
Analystsn/a
Price Targetn/a
Earnings DateAug 31, 2026

About Optimi Health

Optimi Health Corp. operates as a pharmaceutical and nutraceutical drug manufacturing company in Canada. The company manufactures controlled substances including finished MDMA and psilocybin drug products, supplying them directly to authorized clinics, pharmacies, clinical trials, and partners. The company produces and supplies MDMA, natural psilocybin, psilocin, other psychedelic substances, and functional mushrooms derived from botanical sources for health and wellness markets. The company also engages in farming, processing, and distribution... [Read more]

Sector Healthcare
Founded 2020
Employees 8
Stock Exchange Canadian Securities Exchange
Ticker Symbol OPTI
Full Company Profile

Financial Performance

In fiscal year 2025, Optimi Health's revenue was 426,301, an increase of 9.35% compared to the previous year's 389,850. Losses were -3.71 million, -38.50% less than in 2024.

Financial Statements

News

Optimi Health completes first export of naturally derived psilocybin to the UK

Optimi Health (OPTH) announced the completion of its first export of naturally derived psilocybin to the United Kingdom in support of a planned Phase 2 clinical trial. The shipment comprises…

16 hours ago - TheFly

Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial

The shipment of naturally derived psilocybin, comprising both biomass and 5mg capsules, supports a planned Phase 2 clinical trial in the United Kingdom and was completed under export authorization fro...

16 hours ago - GlobeNewsWire

Optimi Health commences finished ibogaine drug product development

Optimi Health (OPTH) provided an update on its recently announced “Ibogaine Initiative,” stating that Optimi has secured naturally derived ibogaine from two sources, in both hydrochloride and freebase...

2 days ago - TheFly

Optimi Health secures ibogaine supply

Optimi Health (OPTH) provided an update on its recently announced Ibogaine initiative. Optimi has secured naturally derived ibogaine from two sources, in both hydrochloride and freebase form. Developm...

2 days ago - TheFly

Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development

Recent US executive order named ibogaine compounds among the psychedelic therapies prioritized for accelerated FDA review and expanded patient access Ibogaine is under investigation to treat PTSD, opi...

2 days ago - GlobeNewsWire

Optimi Health completes commercial production of psilocybin capsules

Optimi Health (OPTH) announced the completion of a good manufacturing practice production run of its 5mg psilocybin finished drug product. The capsules use the same formulation currently prescribed in...

8 days ago - TheFly

Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia

Optimi's 5mg psilocybin capsules are prescribed commercially for treatment-resistant depression in Australia, with additional product from the run earmarked for planned clinical trials in the United S...

8 days ago - GlobeNewsWire

Optimi Health reports expanded psychedelic-assisted therapy access in Australia

Optimi Health (OPTH) acknowledged the final recommendations published by the Therapeutic Goods Administration following its targeted consultation on the Authorized Prescriber, or AP, scheme for psiloc...

12 days ago - TheFly

Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia

Updated TGA recommendations broaden therapist eligibility, accept a wider range of treatment settings, and reinforce Australia's position as the world's leading commercial market for prescribed psiloc...

12 days ago - GlobeNewsWire

Psychedelic: Optimi Health advances natural psilocybin extract

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a production run completion, an IRB approval and a rights expansion. OPTIMI…

13 days ago - TheFly

Diamond Equity Research Initiates Coverage on Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN)

New York, May 27, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research LLC, an equity research firm with a focus on small capitalization public companies has initiated coverage of Optimi Health Corp. (NAS...

14 days ago - GlobeNewsWire

Optimi Health Advances Highest-Purity Natural Psilocybin Extract to Date

The 6% naturally derived extract is set to be encapsulated for use in patients suffering from treatment-resistant depression under Australia's Authorised Prescriber Scheme, where no serious adverse ev...

15 days ago - Newsfile Corp

Optimi Health Announces Closing of Oversubscribed US$15 Million Public Offering

Vancouver, British Columbia--(Newsfile Corp. - May 21, 2026) - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focused...

20 days ago - Newsfile Corp

SRx Health Solutions and EMJX Invest in Recent IPO and Commercial-Stage Pharmaceutical Company of Psychedelics, Optimi Health Corp. (OPTH)

NORTH PALM BEACH, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the "Company") and EMJ Crypto Technologies ("EMJX"), a digital-asset treasury operating platf...

20 days ago - GlobeNewsWire

Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting

Common Shares to Trade on the Nasdaq Capital Market Under the Symbol "OPTH" Vancouver, British Columbia--(Newsfile Corp. - May 20, 2026) - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (th...

21 days ago - Newsfile Corp

Optimi Health Files LIFE Offering Document in Connection with NASDAQ Listing

Vancouver, British Columbia--(Newsfile Corp. - April 23, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer o...

6 weeks ago - Newsfile Corp

Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products

The Company's Health Canada-licensed GMP psychedelic manufacturing platform ready to serve emerging demand for ibogaine, a naturally occurring alkaloid under investigation for opioid use disorder, PTS...

7 weeks ago - Newsfile Corp

Optimi Health Announces Proposed Nasdaq Listing and U.S. Underwritten Public Offering

Vancouver, British Columbia--(Newsfile Corp. - March 16, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focuse...

3 months ago - Newsfile Corp

Optimi Health Reports Early Clinical Rollout of Natural Psilocybin Capsules for Treatment-Resistant Depression in Australia

First Patients of 2026 Treated Outside of Sponsor-Led Clinical Trials Under Australia's Regulated Framework Vancouver, British Columbia--(Newsfile Corp. - February 26, 2026) - Optimi Health Corp. (CSE...

3 months ago - Newsfile Corp

Optimi Health Completes Psilocybin Export to Australia for Treatment Resistant Depression

Naturally-Derived 5 mg Psilocybin Capsules Mark the Company's Second Drug in Market Under Australia's Authorised Prescriber Scheme Vancouver, British Columbia--(Newsfile Corp. - February 19, 2026) - O...

3 months ago - Newsfile Corp

Optimi Health Completes First 2026 Production of MDMA and Psilocybin Capsules

Australia's Department of Health has issued import permits for Optimi's MDMA and psilocybin capsules for use under the Authorised Prescriber Scheme Vancouver, British Columbia--(Newsfile Corp. - Janua...

4 months ago - Newsfile Corp

Optimi Health Announces Equity Incentive Grants and Corporate Update

Vancouver, British Columbia--(Newsfile Corp. - January 16, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian GMP-compliant manufacturer of MDMA ...

5 months ago - Newsfile Corp

Optimi Health to Present at the Sidoti Micro-Cap Conference on January 21-22, 2026

Vancouver, British Columbia--(Newsfile Corp. - January 14, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a leading producer of prescribed psychedelic t...

5 months ago - Newsfile Corp

Optimi Health to Supply MDMA to MAPS Israel's Clinical Trial for Trauma-Related PTSD

Approved multicenter study sponsored by Sheba Medical Center to compare group and individual MDMA-assisted therapy for 168 patients experiencing trauma-related PTSD Vancouver, British Columbia--(Newsf...

7 months ago - Newsfile Corp

Optimi Health's Psilocybin Capsules Selected for Medibank Insurance Program

Australia's largest private health insurer expands its AUD $10M psychotherapy program to cover psilocybin for Treatment-Resistant Depression, building on earlier MDMA coverage for PTSD Vancouver, Brit...

8 months ago - Newsfile Corp